Abstract
Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have been implicated in angiogenesis, tumor growth and invasion, apoptosis resistance and suppression of anti-tumor immunity. Recent studies also revealed that PGE2 signaling may confer cells resistant to targeted growth factor receptor therapy by cross-activation of the receptor signaling pathway downstream components. Pre-clinical studies in animal tumor models have shown tumor reduction when animals are treated with COX-2 inhibitors and have demonstrated promising results when COX-2 inhibitors were combined with chemotherapeutic drugs. Based on these observations several ongoing clinical trials are currently evaluating COX-2 inhibitors as adjuvants with chemotherapy or radiation therapy in patients with advanced non-small cell lung cancer. Further understanding of the mechanisms of COX-2 in tumorigenesis and its interaction with other cellular pathways may highlight the new diagnostic, prognostic and therapeutic markers and facilitate future development of targeted strategies for lung cancer treatment and prevention.
Keywords: Cyclooxygenase, COX inhibitors, COX-2, lung cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Volume: 6 Issue: 3
Author(s): Kostyantyn Krysan, Karen L. Reckamp, Sherven Sharma and Steven M. Dubinett
Affiliation:
Keywords: Cyclooxygenase, COX inhibitors, COX-2, lung cancer
Abstract: Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have been implicated in angiogenesis, tumor growth and invasion, apoptosis resistance and suppression of anti-tumor immunity. Recent studies also revealed that PGE2 signaling may confer cells resistant to targeted growth factor receptor therapy by cross-activation of the receptor signaling pathway downstream components. Pre-clinical studies in animal tumor models have shown tumor reduction when animals are treated with COX-2 inhibitors and have demonstrated promising results when COX-2 inhibitors were combined with chemotherapeutic drugs. Based on these observations several ongoing clinical trials are currently evaluating COX-2 inhibitors as adjuvants with chemotherapy or radiation therapy in patients with advanced non-small cell lung cancer. Further understanding of the mechanisms of COX-2 in tumorigenesis and its interaction with other cellular pathways may highlight the new diagnostic, prognostic and therapeutic markers and facilitate future development of targeted strategies for lung cancer treatment and prevention.
Export Options
About this article
Cite this article as:
Krysan Kostyantyn, Reckamp L. Karen, Sharma Sherven and Dubinett M. Steven, The Potential and Rationale for COX-2 Inhibitors in Lung Cancer, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (3) . https://dx.doi.org/10.2174/187152006776930882
DOI https://dx.doi.org/10.2174/187152006776930882 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Protein Arrays: Recent Achievements and their Application to Study the Human Proteome
Current Proteomics P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Blocking HIV-1 Vif Restores a Natural Mechanism of Intracellular Antiviral Defense
Current Drug Targets - Immune, Endocrine & Metabolic Disorders CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design How Cancer Cells Resist Chemotherapy: Design and Development of Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Pseudogene PTENP1 Suppresses Gastric Cancer Progression by Modulating PTEN
Anti-Cancer Agents in Medicinal Chemistry A Long Time History of a Mediastinal Fibrosis with Triple Vascular Stenosis
Current Respiratory Medicine Reviews Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine Opinion Paper Whatever It Takes
Current Nutrition & Food Science Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews